The Stem Cell Research Controversy: Then and Now (2026)

Originally published January 5, 2011. Updated November 2026 with current science, policy and sources.

Key takeaways

The stem cell research controversy centers on human embryonic stem cells, because deriving them destroys an early embryo, usually a surplus IVF embryo donated with consent.
U.S. policy has swung with each administration: Bush limited federal funding in 2001, Obama expanded it in 2009, and in January 2026 NIH paused approval of new embryonic stem cell lines while it reviews alternatives.
Induced pluripotent stem (iPS) cells, discovered in 2006–2007, reduced (but did not end) reliance on embryos.
Today’s flashpoints are gene editing, lab-grown embryo models and unproven “stem cell clinics,” not just embryos.
FDA-approved stem cell treatments exist, but they are mostly blood-forming stem cell products. Many clinic offerings are not approved.

Few areas of science have created as much hope, and as much argument, as stem cell research. Over the past quarter century, stem cell technology has sparked a controversy over embryos, cloning, genetic engineering and more. When I first wrote this article in 2011, the debate felt brand new. Fifteen years later, it is still one of the most divisive bioethics issues of our time, even though the science and the battle lines have shifted.

What are stem cells?

A stem cell is a cell that can renew itself and develop into other, more specialized cell types in the body. When a stem cell divides, each new cell can either remain a stem cell or become a cell with a more specialized function, such as a brain cell, red blood cell or muscle cell [1]. The idea goes back to the late 1800s and early 1900s, when researchers proposed that the different types of blood cells all originated from a common “stem cell.” Canadian scientists James Till and Ernest McCulloch provided the experimental proof in 1961 (read more in our post on Till and McCulloch’s 1961 discovery, or start with the basics on what a stem cell is).

Because of that flexibility, stem cells are being studied for spinal cord injury, diabetes, heart disease, blood disorders, Parkinson’s disease and many other conditions. Some of that promise has already arrived, and much of it is still in clinical trials. That’s why it pays to be careful about anyone who promises a cure today.

Embryonic vs. adult vs. iPS stem cells

When I wrote the original version of this article, scientists mainly worked with two types of stem cells: adult and embryonic. Today there are three main categories worth knowing (see the glossary for the terms).

Embryonic stem cells are where most of the controversy lies, because they are taken from an early embryo, and the embryo is destroyed in the process. The embryos used in research are not conceived in a woman’s body. They are created by in vitro fertilization at a fertility clinic, and the extras are donated for research with the informed consent of the donors [1]. If they are not donated, these embryos stay frozen indefinitely or are discarded. This is why many supporters argue that using them for research cannot fairly be compared to destroying a human life when the embryo was never going to be implanted. Opponents answer that an embryo is already a human life at its earliest stage, whatever its eventual fate. That disagreement is the heart of the debate.

Adult (somatic) stem cells are found among the specialized cells of a tissue or organ, such as bone marrow. They can renew themselves and become some of the cell types of that tissue. They are far less controversial because they can come from the patient who needs the therapy. Stem cells also come from umbilical cord blood. Families can bank a newborn’s cord blood privately or donate it to a public bank, and if it is not collected it is usually discarded. Cord blood stem cells are a proven treatment for certain blood and immune disorders. In fact, the stem cell products the FDA has approved are blood-forming stem cells derived from cord blood [15].

Induced pluripotent stem (iPS) cells changed the conversation. In 2006, Shinya Yamanaka showed that ordinary mouse skin cells could be reprogrammed into an embryonic-like state, and in 2007 his team and James Thomson’s team did the same with human cells. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon for this work [8]. iPS cells let researchers study patient-specific cells without using embryos, though many scientists still treat embryonic stem cells as the reference standard. For the full story, see what iPS cells changed.

The policy timeline: from Bush to 2026

Because it touches science, ethics and religion all at once, stem cell research has always been political. Since 1996, the Dickey-Wicker Amendment has barred federal funds for research that creates or destroys human embryos, which means the NIH can’t pay to derive new embryonic stem cell lines. The fight has been over research on lines that already exist. Our guide to U.S. embryonic stem cell policy covers this in depth, but here are the turning points:

August 9, 2001: President George W. Bush announced that federal funding could only support embryonic stem cell lines created before that date [2]. More than 60 lines were said to qualify, but in practice only about 21 proved useful to researchers [3]. Private funding was still allowed, but scientists argued that the limits slowed U.S. research while other countries moved ahead.
January 2009: The FDA cleared Geron Corporation to start the first human clinical trial of a therapy derived from embryonic stem cells, for spinal cord injury. Geron halted that trial in November 2011 for business reasons, after treating four patients [6].
March 9, 2009: President Barack Obama signed Executive Order 13505, removing the Bush-era limits and allowing NIH to fund research on many more embryonic stem cell lines [4][5].
2010–2013: In Sherley v. Sebelius, researchers sued, arguing that the Obama policy violated Dickey-Wicker. A judge briefly blocked funding in 2010, the appeals court sided with NIH, and in January 2013 the Supreme Court declined to hear the case, leaving funding in place [7].
2019–2021: The Trump administration restricted federally funded research using human fetal tissue in 2019, and the Biden administration reversed those added restrictions in April 2021 [9].
January 2026: NIH ended funding for research using fetal tissue from elective abortions [16]. A day later it paused approval of new embryonic stem cell lines for its registry and asked the public whether iPS cells and other alternatives could reduce or replace their use. The 503 lines already on the registry can still be used [17]. The comment period closed in April 2026, and as of this update NIH still lists the pause as in effect.

In other words, the same argument that started this article in 2011 is very much alive in 2026. Scientific groups like the ISSCR have urged NIH to keep supporting embryonic stem cell research, while supporters of the pause say newer models make embryos less necessary.

The ethical arguments

Opponents of embryonic stem cell research believe that destroying an embryo for research is immoral, no matter how promising the science. Supporters believe it is morally wrong to throw away an embryo that will never be implanted when it could help produce treatments for millions of people. Both sides include people of good faith, and the issue is not as black and white as it is often portrayed.

There are gray areas, too. Some opponents of embryonic research support adult stem cell research, while others oppose both. Even strong supporters worry about how the technology could be abused. When I first wrote about “designer babies,” it was a hypothetical. In November 2018, Chinese scientist He Jiankui announced that he had used CRISPR gene editing on human embryos that became twin girls. The scientific world condemned the experiment, and in December 2019 a Chinese court sentenced him to three years in prison [10]. That case showed why oversight matters. At the same time, many supporters have much more personal reasons for caring, such as the hope of saving a dying relative before it is too late.

Where the debate stands today

The controversy has grown well beyond embryos. Here is where it stands in late 2026:

Approved therapies are real. In December 2023, the FDA approved Casgevy, the first therapy using CRISPR gene editing, and Lyfgenia for sickle cell disease. Both work by modifying a patient’s own blood stem cells [13]. In April 2023, the FDA approved Omisirge, a therapy made from donated umbilical cord blood for patients with blood cancers [14].
Embryo research rules have changed. In 2021, the International Society for Stem Cell Research (ISSCR) dropped its strict 14-day limit on growing human embryos in the lab, saying such research should be reviewed case by case instead [11]. In 2025, it updated its guidelines for stem cell–based embryo models, requiring oversight for all 3D models and banning attempts to grow them to viability [12].
Unproven clinics are a growing concern. The FDA warns that many clinics sell unapproved “stem cell” products for conditions like arthritis, back pain, autism or Parkinson’s, and it has received reports of blindness, tumors and infections [15]. If a clinic charges you to join a “trial,” ask for its FDA IND number.
Federal policy is in flux. As noted above, the NIH pause on new embryonic stem cell lines and the 2026 fetal tissue rule mean U.S. funding rules may keep changing [16][17].

To follow the latest developments, see the headlines on our sister site, Stem Cell Tracker [20], and the milestones on our stem cell timeline.

Fire, the Internet and Galileo: why progress is always contested

Each side of the ethical debate is neither entirely right nor entirely wrong, because so much of it rests on personal beliefs. Some will see the whole enterprise as destructive and immoral, while others will see it as one of the greatest advances in scientific history. It is natural for humans to fear the unknown, and the status quo rarely changes without a fight. Galileo, often called the father of modern science, spent the last years of his life under house arrest after the Church condemned him in 1633 for defending the idea that the Earth moves around the Sun [19].

The ability to make fire was one of the most important discoveries in our history. It let us see in the dark, stay warm and cook our food safely. It was also used to destroy villages and burn people at the stake. Would humanity have been better off without it? Of course not. The same goes for the Internet. It connects the world and puts nearly unlimited information at our fingertips, but it also gives cover to predators and criminals. Both points are true, and neither settles the question of the Internet’s morality, because technology does not have a moral compass. It is only as good or as evil as the person, or society, using it.

So this debate is not only about whether stem cell research is ethical. It is about whether we can trust ourselves to handle its enormous potential responsibly. Humans are fallible, but that does not mean we should dismiss innovation. Instead, we have to adapt to our own advances and work together to protect ourselves from…ourselves.

My take

I personally support stem cell research. Not because I dream of immortality, but because I believe it is unfair for an embryo that will never have the chance to experience life to be sentenced to a purposeless end, especially when it could be used to save another life. To me, that is the moral thing to do, and those are the values I would want to pass down to future generations.

Fifteen years after I first wrote this, I’m glad that iPS cells, gene-edited stem cell therapies and stronger oversight have taken some of the heat out of the argument. But the stem cell debate is not going to go away. As the saying popularly credited to Victor Hugo goes, “Nothing can stop an idea whose time has come.” (Hugo’s actual 1877 line was closer to “One can resist the invasion of armies; one cannot resist the invasion of ideas” [18].)

Frequently asked questions

Why is stem cell research controversial?

The controversy is mainly about human embryonic stem cells. Deriving them destroys an early embryo, usually a surplus IVF embryo donated with consent. People who believe an embryo has the moral status of a person object. Adult, cord blood and iPS stem cell research is far less controversial.

Is embryonic stem cell research legal in the United States?

Yes. No federal law bans privately funded embryonic stem cell research, though some states regulate it. Federal funds can’t be used to create or destroy embryos under the Dickey-Wicker Amendment. NIH can fund research on approved existing lines, but it paused approval of new lines in January 2026 [17].

Do iPS cells end the need for embryonic stem cells?

Not entirely. iPS cells avoid destroying embryos and are now widely used, but many researchers still use embryonic stem cells as a comparison standard. That question is exactly what NIH asked the public to weigh in on in 2026 [17].

Are there FDA-approved stem cell treatments?

Yes, but only a small number, mostly blood-forming stem cell products from cord blood, plus gene therapies built on a patient’s own blood stem cells, such as Casgevy and Lyfgenia [13][15]. Be wary of clinics selling stem cell treatments for other conditions.

References

Educational content only; not medical, legal or policy advice.